The complement and immunoglobulin levels in NMO patients

Neurological Sciences

Volumn 35, Issue 2, 2014, Pages 215-220

  Chen, Ying ^a   Li, Rui ^a   Wu, Ai Ming ^a   Shu, Ya Qing ^a   Lu, Zheng Qi ^a   Hu, Xue Qiang ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

AQP4; Complement; EDSS; Immunoglobulin; NMO

Indexed keywords

ACUTE DISEASE; ADULT; ANTIBODIES; AQUAPORIN 4; COMPLEMENT C3; COMPLEMENT C4; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN M; MALE; NEUROMYELITIS OPTICA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84893842079     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-013-1481-y     Document Type: Article

References (31)

1. Magana SM et al (2009) Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol 66(8):964-966
2. Papadopoulos MC, Verkman AS (2012) Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11(6):535-544
3. Lucchinetti CF et al (2002) A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125(Pt 7):1450-1461 (Pubitemid 34755161)
4. Correale J, Fiol M (2004) Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 63(12):2363-2370 (Pubitemid 40024351)
5. Padilla-Docal B et al (2007) C3c intrathecal synthesis evaluation in patients with multiple sclerosis. Arq Neuropsiquiatr 65(3B):800-802 (Pubitemid 47623446)
6. Bruck W, Stadelmann C (2003) Inflammation and degeneration in multiple sclerosis. Neurol Sci 24(Suppl 5):S265-S267 (Pubitemid 37493197)
7. Nataf S et al (2000) Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol 165(10):5867-5873
8. Hinson SR et al (2012) Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA 109(4):1245-1250
9. Kinoshita M, Nakatsuji Y (2012) Where do AQP4 antibodies fit in the pathogenesis of NMO? Mult Scler Int 2012:862169
10. Mader S et al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:184
11. Wingerchuk DM et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485-1489 (Pubitemid 43958540)
12. Fujita T, Matsushita M, Endo Y (2004) The lectin-complement pathway-its role in innate immunity and evolution. Immunol Rev 198:185-202 (Pubitemid 38406944)
13. Mastellos D et al (2003) Complement: structure, functions, evolution, and viral molecular mimicry. Immunol Res 27(2-3):367-386 (Pubitemid 36995019)
14. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344(14):1058-1066 (Pubitemid 32267977)
15. Zhang B et al (2008) Correlation between serum thyroxine and complements in patients with multiple sclerosis and neuromyelitis optica. Neuro Endocrinol Lett 29(2):256-260 (Pubitemid 351659376)
16. Gorevic PD (2012) Rheumatoid factor, complement, and mixed cryoglobulinemia. Clin Dev Immunol 2012:439018
17. Karp DR (2005) Complement and systemic lupus erythematosus. Curr Opin Rheumatol 17(5):538-542 (Pubitemid 41527812)
18. Di Muzio G et al (2011) Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment. Int J Immunopathol Pharmacol 24(2):357-366
19. Barnum SR, Szalai AJ (2006) Complement and demyelinating disease: no MAC needed? Brain Res Rev 52(1):58-68 (Pubitemid 44051532)
20. Cojocaru M, Serbanescu A, Cojocaru IM (1993) Changes of serum complement and of circulating immune complexes in patients with multiple sclerosis. Rom J Intern Med 31(2):131-137
21. Tsukamoto H, Horiuchi T (2006) Clinical aspects of the complement system. Rinsho Byori 54(7):757-762
22. Akiyama H et al (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21(3):383-421 (Pubitemid 30349107)
23. Hinson SR et al (2007) Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69(24):2221-2231 (Pubitemid 350294677)
24. Saadoun S et al (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133(Pt 2):349-361
25. Sabater L et al (2009) Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol 215(1-2):31-35
26. Hinson SR et al (2009) Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol 66(9):1164-1167
27. Jarius S et al (2010) Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med 48(5):659-663
28. Lennon VA et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106-2112 (Pubitemid 39626806)
29. Lennon VA et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473-477 (Pubitemid 41186945)
30. Misu T et al (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130(Pt 5):1224-1234 (Pubitemid 47355951)
31. Ratelade J, Verkman AS (2012) Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol 44(9):1519-1530